History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
Open Access
- 10 January 2023
- journal article
- research article
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 6, 100133
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- The history of the development of buprenorphine as an addiction therapeuticAnnals of the New York Academy of Sciences, 2012
- Patterns in admission delays to outpatient methadone treatment in the United StatesJournal of Substance Abuse Treatment, 2011
- The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care‐led methadone maintenance serviceAddiction, 2010
- Buprenorphine Duration of Action: Mu-opioid Receptor Availability and Pharmacokinetic and Behavioral IndicesBiological Psychiatry, 2007
- Medications development: Successes and challengesPharmacology & Therapeutics, 2005
- Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and NaloxoneNew England Journal of Medicine, 2003
- Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent VolunteersNeuropsychopharmacology, 2003
- From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United StatesDrug and Alcohol Dependence, 2003
- Effects of buprenorphine and naloxone in morphine-stabilized opioid addictsDrug and Alcohol Dependence, 1998
- Bioavailability of Sublingual BuprenorphineThe Journal of Clinical Pharmacology, 1997